Newsroom
Get the latest news and press releases from CathWorks, plus upcoming events and useful information for physicians, patients, and media.
Filter
Press Release
CathWorks Adds Vice President of Global Marketing to Leadership Team
Feb 25, 2019
CathWorks announced that Ramin Mousavi has joined as Vice President of Global Marketing & Strategy to take responsibility
Read MorePress Release
CathWorks Announces Completion Of $30 Million Financing
Feb 04, 2019
CathWorks announced the completion of a $30 million Series C financing round led by Deerfield Management.
Read MorePress Release
CathWorks Names Paul Kapsner as Vice President of Sales
Dec 27, 2018
CathWorks announced that Paul Kapsner has been named as Global Vice President of Sales.
Read MorePress Release
CathWorks FFRangio™ System Receives U.S. FDA Clearance
Dec 20, 2018
CathWorks announced today that its FFRangio™ System received United States Food & Drug Administration (FDA) 510(k) clearance.
Read MorePress Release
CathWorks FFRangio™ Trial Meets Primary Enpoint and Exceeds Performance Goals
Sep 24, 2018
The journal Circulation published results from the CathWorks FFRangio™ FAST-FFR clinical trial in an article titled Accuracy of Fractional Flow Reserve Derived From Coronary Angiography.
Read MorePress Release
CathWorks FFRangio™ System Clinical Review Featured in TCT 2018 Program
Sep 12, 2018
The CathWorks FFRangio™ System will be featured in a TCT Lunch Presentation Theater Program held during the 2018 TCT (Transcatheter Cardiovascular Therapeutics) annual meeting in San Diego.
Read MorePress Release
FAST-FFR Pivotal Trial Added To TCT 2018 Late-Breaking Clinical Trial Program
Aug 29, 2018
CathWorks announced that the FAST-FFR pivotal trial has been added to the late-breaking clinical science program during the 2018 TCT (Transcatheter Cardiovascular Therapeutics) annual meeting in San Diego.
Read MorePress Release
CathWorks FFRangio™ System files FDA 510(k) Submission
Aug 22, 2018
CathWorks announced that it has submitted its CathWorks FFRangio™ System to the United States Food & Drug Administration (FDA) for review and 510(k) market clearance.
Read More